Table 1.

Eligibility criteria of the ixazomib named patient program

Patient is = > 18 years of age

Patient is diagnosed with multiple myeloma according to standard criteria

Patient has received 1 to 3 prior lines of therapy

Patient is in biochemical or symptomatic relapse and is not on an active anti-myeloma therapy (except for steroids) at the time of this application

Next planned therapy for the patient is ixazomib in combination with lenalidomide and dexamethasone

Patient is not refractory to lenalidomide or a proteasome inhibitor, or was not refractory to lenalidomide or proteasome inhibitor-based therapy at any line.

Absolute neutrophil count = > 1000/mm3 and platelet count = > 75,000/mm3;

Total bilirubin <= 1.5 x upper limit of normal;

Alanine aminotransferase and aspartate aminotransferase <= 3 x upper limit of normal;

Calculated creatinine clearance = > 30 mL/min

Patient has an ECOG performance status score of 0, 1 or 2

Both males and females have agreed to use an effective contraception method during and for 90 days following treatment.